σellas life sciences is a healthcare-oriented global group of companies with a unique and innovative vision, which is ambitious, yet clear: to practice the medicine of tomorrow, today. in other words, we incorporate innovation throughout all our activities aiming at breakthroughs that will have a significant impact on the thinking and practicing of healthcare worldwide. our international team of acknowledged scientists, doctors and health professionals along with a seasoned and highly experienced pharmaceutical executive management form the core of σellas. we strive to improve patients' quality of life through developing and commercializing cutting-edge drugs, medical devices and innovative therapies.
Company profile
Ticker
SLS
Exchange
Website
CEO
Angelos M. Stergiou
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Galena Biopharma, Inc., RXi Pharmaceuticals Corp, GALENA BIOPHARMA, INC.
SEC CIK
Corporate docs
Subsidiaries
Sellas Life Sciences Limited • Sellas Life Sciences Group Ltd. • SLSG Limited LLC • Apthera, Inc. ...
SLS stock data
Latest filings (excl ownership)
D
$18.37 mm in options / securities to be acquired, sold $18.37 mm, 4 investors
29 Mar 24
S-3
Shelf registration
28 Mar 24
S-3
Shelf registration
28 Mar 24
8-K
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Other Events
28 Mar 24
424B5
Prospectus supplement for primary offering
18 Mar 24
8-K
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
15 Mar 24
8-K
Other Events
11 Mar 24
8-K
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
8 Mar 24
Transcripts
Latest ownership filings
SC 13G
HIGHBRIDGE CAPITAL MANAGEMENT LLC
7 Feb 24
4
Angelos M. Stergiou
25 Jan 24
4
DAVID A SCHEINBERG
25 Jan 24
4
BARBARA A WOOD
25 Jan 24
4
Katherine Bach Kalin
25 Jan 24
4
Jane Wasman
25 Jan 24
4
Robert Francomano
25 Jan 24
4
John Varian
25 Jan 24
4
NOSTRAND ROBERT L VAN
25 Jan 24
4
John Thomas Burns
25 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.07 mm | 4.07 mm | 4.07 mm | 4.07 mm | 4.07 mm | 4.07 mm |
Cash burn (monthly) | 3.28 mm | 1.45 mm | 3.12 mm | 3.26 mm | 2.30 mm | 2.64 mm |
Cash used (since last report) | 22.64 mm | 10.00 mm | 21.54 mm | 22.52 mm | 15.86 mm | 18.26 mm |
Cash remaining | -18.57 mm | -5.93 mm | -17.47 mm | -18.45 mm | -11.79 mm | -14.19 mm |
Runway (months of cash) | -5.7 | -4.1 | -5.6 | -5.7 | -5.1 | -5.4 |
Institutional ownership, Q2 2023
7.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 27 |
Opened positions | 4 |
Closed positions | 5 |
Increased positions | 8 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 4.86 bn |
Total shares | 4.26 mm |
Total puts | 25.00 k |
Total calls | 1.59 mm |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Alyeska Investment | 1.25 mm | $1.96 bn |
Vanguard | 946.71 k | $1.49 bn |
Equilibria Capital Management | 643.26 k | $37.63 mm |
CVI Investments | 315.25 k | $1.83 mm |
BLK Blackrock | 283.37 k | $444.89 mm |
Hirschman Orin | 190.00 k | $1.59 mm |
Geode Capital Management | 188.07 k | $295.26 mm |
EQH Equitable | 135.00 k | $211.95 mm |
STT State Street | 97.13 k | $152.49 mm |
NTRS Northern Trust | 39.36 k | $61.80 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Jan 24 | Wasman Jane | Common Stock | Grant | Acquire A | No | No | 0 | 6,000 | 0.00 | 10,400 |
22 Jan 24 | Wasman Jane | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5195 | 10,000 | 5.20 k | 10,000 |
22 Jan 24 | Francomano Robert | Common Stock | Grant | Acquire A | No | No | 0 | 20,000 | 0.00 | 40,918 |
22 Jan 24 | Francomano Robert | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5195 | 30,000 | 15.58 k | 30,000 |
22 Jan 24 | Varian John | Common Stock | Grant | Acquire A | No | No | 0 | 6,000 | 0.00 | 10,400 |
22 Jan 24 | Varian John | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5195 | 10,000 | 5.20 k | 10,000 |
22 Jan 24 | Van Nostrand Robert L | Common Stock | Grant | Acquire A | No | No | 0 | 6,000 | 0.00 | 10,400 |
22 Jan 24 | Van Nostrand Robert L | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5195 | 10,000 | 5.20 k | 10,000 |
22 Jan 24 | Burns John Thomas | Common Stock | Grant | Acquire A | No | No | 0 | 47,000 | 0.00 | 101,927 |
22 Jan 24 | Burns John Thomas | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5195 | 75,000 | 38.96 k | 75,000 |
News
SELLAS Life Sciences Gr Q4 EPS $(0.25) Misses $(0.21) Estimate
28 Mar 24
SELLAS Announces Topline Data From Phase 2a Study of SLS009 In Relapsed/Refractory Acute Myeloid Leukemia And Provides Steering Committee Update on Phase 3 REGAL Study
26 Mar 24
Dow Falls Over 200 Points; Adobe Shares Plunge
15 Mar 24
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
15 Mar 24
12 Health Care Stocks Moving In Friday's Intraday Session
15 Mar 24
Press releases
GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma
28 Mar 24
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
26 Mar 24
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
19 Mar 24
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
15 Mar 24
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
8 Mar 24